An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Moderate to Severe Ankylosing Spondylitis.
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 06 Aug 2015 Results published in the Annals of the Rheumatic Diseases.
- 04 Mar 2013 New trial record